share_log

先瑞達醫療-B(06669.HK):動靜脈導入DCB產品上市許可申請獲受理

First Ruida Medical-B (06669.HK): application for marketing license for arteriovenous introduction of DCB products is accepted

即市頭條 ·  Jan 18, 2022 03:45

First Ruida Medical-B (06669.HK) announced that on January 17 this year, the State Drug Administration accepted its application for registration of AcoArt Orchid&Dhalia for the treatment of arteriovenous stenosis (AVF).

AVF is an artificially opened channel between arteries and veins for hemodialysis in patients with end-stage renal disease (ESRD). However, due to periodic trauma and hemodynamic changes, the vessel is easy to cause stenosis, and DCB can effectively treat the stenosis.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment